Showing 681 - 700 results of 761 for search '"placebo"', query time: 0.08s Refine Results
  1. 681

    Thiamine-Reduced Fatigue in Quiescent Inflammatory Bowel Disease Is Linked to Faecalibacterium prausnitzii Abundance by Sandra Bermúdez-Sánchez, Palle Bager, Jens Frederik Dahlerup, Simon Mark Dahl Baunwall, Tine Rask Licht, Martin Steen Mortensen, Christian Lodberg Hvas

    Published 2025-01-01
    “…The 40 patients with qIBD and fatigue were included in a randomized, placebo-controlled, crossover trial to assess a 4-week high-oral-dose thiamine regimen. …”
    Get full text
    Article
  2. 682

    Vitamin D Supplementation and Hemoglobin Levels in Hypertensive Patients: A Randomized Controlled Trial by Jana B. Ernst, Andreas Tomaschitz, Martin R. Grübler, Martin Gaksch, Katharina Kienreich, Nicolas Verheyen, Winfried März, Stefan Pilz, Armin Zittermann

    Published 2016-01-01
    “…Patients randomly received 2800 IU vitamin D3 daily or a matching placebo for eight weeks. Initially, the prevalence of anemic status (Hb levels <12.5 g/dL) and deficient 25OHD levels (<30 nmol/L) was 6.5% and 7.5%, respectively. …”
    Get full text
    Article
  3. 683

    Early effects of LT3 + LT4 combination therapy on quality of life in hypothyroid patients: a randomized, double-blind, parallel-group comparison trial by Fatemeh Hajtalebi, Fariba Alaei-Shahmiri, Fatemeh Golgiri, Najmeh Shahini, Hamideh Akbari, Kasra Assadian, Seyedarad Mosalamiaghili

    Published 2025-01-01
    “…While no significant differences emerged between the groups in terms of blood pressure, lipid profiles (except for low-density lipoprotein cholesterol), or body weight, there were notable improvements in physical functioning and bodily pain in the LT4 + LT3 group compared to the LT4 + placebo group. Compared with baseline, combination therapy significantly increased the physical component summary score after six months, but the difference was not significant. …”
    Get full text
    Article
  4. 684

    Comparative efficacy and safety of 20 intravenous pharmaceutical intervention for prevention of etomidate-induced myoclonus: a systematic review and Bayesian network meta-analysis by Lu Chen, Lu Chen, Pengxiang Zhou, Pengxiang Zhou, Zhengqian Li, Ziyang Wu, Suodi Zhai, Suodi Zhai

    Published 2025-01-01
    “…We included randomized controlled trials (RCTs) comparing intravenous pharmaceutical interventions to prevent EIM with placebo, no intervention, or another pharmaceutical intervention.ResultsForty-eight RCTs involving 4,768 participants randomly assigned to 20 intravenous pharmaceutical interventions and normal saline were included. …”
    Get full text
    Article
  5. 685

    Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis by Fábio Peixoto, Maurício T. Nascimento, Rúbia Costa, Juliana Silva, Gaby Renard, Luiz Henrique Guimarães, Gerson Penna, Manoel Barral-Netto, Lucas P. Carvalho, Paulo R. L. Machado, Edgar M. Carvalho

    Published 2020-01-01
    “…Patients were treated with miltefosine plus GM-CSF, miltefosine plus placebo, or Sbv. Mononuclear cells were stimulated with soluble Leishmania antigen (SLA) on day 0 and day 15 of therapy, and cytokine levels were determined in supernatants by ELISA. …”
    Get full text
    Article
  6. 686
  7. 687

    Effects of melatonin supplementation on oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: a double-blind, randomized controlled trial by Sara Sadeghi, Amirahmad Nassiri, Monir Sadat Hakemi, Fatemeh Hosseini, Fatemeh Pourrezagholie, Fatemeh Naeini, Aylar Nadiri Niri, Hossein Imani, Hamed Mohammadi

    Published 2025-02-01
    “…For ten weeks, participants were randomized to receive either a placebo or 5 mg of melatonin twice a day. Baseline characteristics, dietary intake, physical activity, and anthropometric measurements were recorded. …”
    Get full text
    Article
  8. 688

    The Impact of Atorvastatin on Intraprostatic Biomarkers – Prognostic Value of 3LS-score – Follow-up of ESTO1-Trial by Eemil Lehtonen, Maiju Vertanen, Heimo Syvälä, Teemu Tolonen, Seppo Auriola, Teuvo Tammela, Aino Siltari, Teemu Murtola

    Published 2025-03-01
    “…Methods: The ESTO1 trial randomized 158 statin-naïve PCa patients to receive high-dose atorvastatin (80 mg daily) or placebo before prostatectomy. Long term outcomes were assessed for 102 patients through medical records review. …”
    Get full text
    Article
  9. 689

    Low-Dose Caffeine Supplementation Is a Valuable Strategy for Increasing Time to Exhaustion, Explosive Power, and Reducing Muscle Soreness in Professional Male Kickboxers by Maziar Saremi, Fatemeh Shahriari, Mohammad Hemmatinafar, Rasoul Rezaei, Alireza Niknam, Michael Nordvall, Alexei Wong, Reza Bagheri

    Published 2025-01-01
    “…Methods: Twelve kickboxing athletes participated in 3 exercise sessions with either caffeine supplementation (3 mg/kg [C3], 6 mg/kg [C6]) or placebo (PLA). A 1-wk washout period occurred between exercise trials. …”
    Get full text
    Article
  10. 690
  11. 691

    Comparative effectiveness of manual therapy, pharmacological treatment, exercise therapy, and education for neck pain (COMPETE study): protocol of a systematic review with network... by Ana Izabela Sobral de Oliveira-Souza, Jordana Barbosa-Silva, Douglas P. Gross, Bruno R. da Costa, Nikolaus Ballenberger, Tiago V. Pereira, Liz Dennett, Susan Armijo-Olivo

    Published 2025-01-01
    “…NMAs will be conducted to rank interventions according to their effectiveness and safety (when possible), allowing a comprehensive analysis of all available evidence, with different nodes specified for all conservative interventions of interest, placebo, sham therapy, and non-intervention control. …”
    Get full text
    Article
  12. 692

    Pharmacological Management of Chronic Neuropathic Pain – Consensus Statement and Guidelines from the Canadian Pain Society by DE Moulin, AJ Clark, I Gilron, MA Ware, CPN Watson, BJ Sessle, T Coderre, PK Morley-Forster, J Stinson, A Boulanger, P Peng, GA Finley, P Taenzer, P Squire, D Dion, A Cholkan, A Gilani, A Gordon, J Henry, R Jovey, M Lynch, A Mailis-Gagnon, A Panju, GB Rollman, A Velly

    Published 2007-01-01
    “…Medications are recommended in the guidelines if their analgesic efficacy was supported by at least one methodologically sound, randomized, controlled trial showing significant benefit relative to placebo or another relevant control group. Recommendations for treatment are based on degree of evidence of analgesic efficacy, safety, ease of use and cost-effectiveness. …”
    Get full text
    Article
  13. 693
  14. 694

    Effect of icatibant on sweating-induced dermal pain by Shunsuke Takahagi, Shunsuke Takahagi, Daiki Matsubara, Emi Murakami, Yumi Aoyama, Shinya Imamura, Atsushi Fukunaga, Atsushi Fukunaga, Yoshiko Oda, Hiroyuki Murota, Michihiro Hide, Michihiro Hide

    Published 2025-02-01
    “…Participants randomly received icatibant (30 mg) or placebo on Day 1 and vice versa on Day 2. Before and after drug administration, dermal pain induced by an artificial thermal loading was assessed using the visual analog scale (VAS).ResultsFour patients were enrolled, three of whom completed the full procedure with the termination in the other. …”
    Get full text
    Article
  15. 695

    “Effect of oral systemic administration of vitamin D on the rate of maxillary canine retraction: A randomized controlled trial” by Davender Kumar, Revathi Mn, Rekha Sharma, Ashuma Sachdeva, Nameksh Raj Bhupali, Ravinder Solanki

    Published 2025-03-01
    “…The enrolled patients were randomized and allocated to the experimental group (Oral Vitamin D = 0.25 μg given) and control group (Placebo given). The canine retraction was initiated using nickel-titanium (NiTi) closed coil springs delivering a force of 100 gm per side and Vitamin D levels were monitored at monthly intervals. …”
    Get full text
    Article
  16. 696

    Systematic review and bayesian network meta-analysis: comparative efficacy and safety of six commonly used biologic therapies for moderate-to-severe Crohn’s disease by Haohang Su, Haohang Su, Shengwei Xiao, Zhiqing Liang, Zhiqing Liang, Tianrong Xun, Jinfang Zhang, Jinfang Zhang, Xixiao Yang, Xixiao Yang

    Published 2025-01-01
    “…BackgroundIn contrast to previous network meta-analysis using classical frequentist methods, we evaluated the efficacy and safety of six frequently-used biologics through a Bayesian method.MethodsWeb of Science, Scopus, CENTRAL, ClinicalTrials.gov and ICTRP were searched to collect randomized controlled trials (RCTs) in adults with moderate-to-severe Crohn’s disease, comparing Infliximab, Adalimumab, Certolizumab pegol, Ustekinumab, Risankizumab, or Vedolizumab, relative to placebo or an active comparator for induction of clinical response (two different definitions) and maintenance of clinical remission. …”
    Get full text
    Article
  17. 697

    Effects of vitamin D supplementation in patients with rheumatoid arthritis: A systematic review and meta-analysis by Mahsa Ranjbar, Mehran Rahimlou, Maryam Fallah, Kurosh Djafarian, Hamed Mohammadi

    Published 2025-02-01
    “…Clinical studies involving patients with RA were included if they compared the effects of vitamin D supplementation to either a placebo or standard care. The results from the selected studies were presented as weighted mean differences (WMD) along with a 95 % confidence interval (CI). …”
    Get full text
    Article
  18. 698

    Effect of NaF, SnF2, and TiF4 Toothpastes on Bovine Enamel and Dentin Erosion-Abrasion In Vitro by Lívia Picchi Comar, Marina Franciscon Gomes, Naiana Ito, Priscila Aranda Salomão, Larissa Tercília Grizzo, Ana Carolina Magalhães

    Published 2012-01-01
    “…Bovine enamel and dentin specimens were distributed into 10 groups (n=12): experimental placebo toothpaste (no F); NaF (1450 ppm F); TiF4 (1450 ppm F); SnF2 (1450 ppm F); SnF2 (1100 ppm F) + NaF (350 ppm F); TiF4 (1100 ppm F) + NaF (350 ppm F); commercial toothpaste Pro-Health (SnF2—1100 ppm F + NaF—350 ppm F, Oral B); commercial toothpaste Crest (NaF—1.500 ppm F, Procter & Gamble); abrasion without toothpaste and only erosion. …”
    Get full text
    Article
  19. 699

    Efficacy and Safety of Prophylactic Agents in Prevention of Retinopathy of Prematurity: A Systematic Review and Meta-analysis of Randomised Controlled Trials by Waleed T Batais, Nada O Taher, Abeer K Alhindi, Abdullah A Ghaddaf, Anas Alamoudi, Sarah A Al-Ghamdi, Jumanah J Homsi, Hashem S Almarzouki, Mansour A Qurashi

    Published 2024-12-01
    “…Data were pooled using the inverse variance weighting method and reported as risk ratios (RRs) with 95% CI.Results No significant reduction in ROP incidence at any stage was found in the intervention groups compared with placebo (RR=0.83; 95% CI= (0.69 to 1.00); p=0.05; I²=0%). …”
    Get full text
    Article
  20. 700

    Caregiver Global Impression Observations from EMBARK: A Phase 3 Study Evaluating Delandistrogene Moxeparvovec in Ambulatory Patients with Duchenne Muscular Dystrophy by Craig M. McDonald, Jacob S. Elkins, Sai Dharmarajan, Katherine Gooch, Teofil Ciobanu, Claire J. Lansdall, Alexander P. Murphy, Fiona McDougall, Eugenio M. Mercuri, Ivana Audhya, the EMBARK Study Group

    Published 2024-11-01
    “…Methods In the Phase 3 randomized, double-blind, placebo-controlled trial (EMBARK; NCT05096221), the CaGI-C at week 52 and change from baseline to week 52 in CaGI-S were evaluated in a post hoc analysis. …”
    Get full text
    Article